Introduction The level of administered activity in radionuclide therapy is often limited by
haematological toxicity resulting from the absorbed dose delivered to the bone marrow. The …

Importance Targeted alpha therapy attempts to deliver systemic radiation selectively to cancer
cells while minimizing systemic toxic effects and may lead to additional treatment options …

Background Ocrelizumab is a humanized anti-CD20 antibody with increased antibody-dependent
cellular cytotoxicity compared with rituximab. This phase I/II study evaluated its safety …

Abstract Treatment for follicular lymphoma (FL) improved with rituximab. In Sweden, first-line
rituximab was gradually introduced between 2003 and 2007, with regional differences. The …

Purpose: Fractionated radioimmunotherapy may improve therapeutic outcome by decreasing
heterogeneity of the dose delivered to the tumor and by decreasing hematologic toxicity, …

… Scholz, Antonello Pinto, Werner Linkesch, Ola Lindén, Andreas Viardot, Ulrich Keller, Georg
Hess, Secondo Lastoria, Kristina Lerch, Ferdinando Frigeri, Manuela Arcamone, Andrea Stroux …

Introduction Radionuclide therapy has distinct similarities to, but also profound differences
from external radiotherapy. Review This review discusses techniques and results of …

Discussion The standard treatment for chordoma is surgery and radiotherapy. There is no
recognised effective chemotherapy. The above cited case using two different agents to target …

Purpose: T cells influence outcome in follicular lymphoma, but their contributions seem to
be modified by therapy. Their impact in patients receiving rituximab without chemotherapy is …

The purpose of this phase II randomized trial was to evaluate the effect and safety of
interferon-α2a (IFN) in combination with extended dosing rituximab in patients with symptomatic, …